750
Participants
Start Date
March 31, 2003
T138067 intravenous
doxorubicin intravenous
Zhitomir Regional Hospital, Zhitomir
University of Pennsylvania, Philadelphia
Vinnitsa Regional Clinical Oncological Center, Vinnitsa
VA Medical Center, Miami
University of Miami, Miami
H. Lee Moffitt Cancer Center, Tampa
University of Alabama, Birmingham
Poltava Regional Clinical Oncological Center, Poltava
Khon Kaen University, Khon Kaen
Dnepropetrovsk State Medical Academy, Dnipro
Krivorojsky City Oncology Center, Kryvyi Rih
Chiangmai University, Muang Chiangmai
Loyola University of Chicago, Maywood
Zaporozhje State Medical Institute of Postgraduate Education, Zaporizhzhya
Lvov State Medical University, Lviv
Donetsk Regional Antitumor Center, Donetsk
University of California at San Francisco, San Francisco
Cancer Hospital of Chinese Academy of Medical Science (CAMS), Beijing
Beijing Cancer Hospital of Peking University, Beijing
Gereral Hospital of PLA, Beijing
Blokhin Cancer Research Center, Moscow
National University Hospital, Singapore
Central Clinical Hospital of the President of the Russian Federation, Moscow
Central Clinical Hospital of the Ministry of Transport, Moscow
Arkhangelsk Redional Oncology Center, Department of Chemotherapy, Arkhangelsk
Moscow Oncology Hospital #62, P/O Stepanovskoye
Yaroslavl Regional Oncology Center, Yaroslavl
Central Research Institute of Radiology of the Ministry of Health of Russian Federation, Saint Petersburg
Medical Academy of Postgraduate Education, St. Petersburg, Saint Petersburg
St. Petersburg Mechnikov State Medical Academy, Saint Petersburg
St. Petersburg Oncology Center, Saint Petersburg
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai
Shanghai Changzheng Hospital, Shanghai
Nanjing Ba Yi Hospital of PLA, Nanjing
Russian Academy of Medical Sciences, Obninsk
The Affiliated Hospital of Medical College Qingdao University, Qingdao
Rostov Research Oncology Institute, Rostov-on-Don
Krasnodar City Oncology Center, Krasnodar
Stavropol Regional Oncology Center, Stavropol
Voronezh Regional Clinical Oncology Center, Voronezh
Lipetsk, Lipetsk
Chongqing Southwest Hospital, Chongqing
Kazan State Medical University, Kazan'
Kazan Republican Oncology Clinical Center, Kazan'
Bashkiria Republican Oncology Center, Ufa
Orenburg Regional Oncology Center, Orenburg
Cancer Center, Sun Yat-Sen Unversity, Guangzhou
Guangzhou Nanfang Hospital, Guangzhou
Cheliabinsk Regional Oncology Center, Chelyabinsk
Novosibirks Municipal Clinical Hospital #1, Novosibirsk
Tomsk Regional Research Institute of Oncology, Tomsk
Barnaul
Krasnoyarsk Regional Oncology Center, Krasnoyarsk
Irkutsk Regional Oncology Center, Irkutsk
1st Affiliated Hospital of Xi An Jiao Tong University, Xi’an
Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo
Hospital Vera Cruz, Belo Horizonte
Hospital Mater Dei - Departamento de Oncologia, Belo Horizonte
Irmandade Santa Casa de Misericórdia de Porto Alegre - Unidade de Apoio à Pesquisa, Porto Alegre
UT Southwestern Medical Center - Dallas, Dallas
Queen Mary Hospital, Hong Kong
Taipei Veteran General Hospital, Taipei
Chang Gung Memorial Hospital, Taoyuan
Prince Wales Hosptial, Hong Kong
Omsk Regional Oncology Center, Omsk
Eastern Cape Oncology Centre, Port Elizabeth
Katedra i Klinika Onkologii i Radioterapi Akademii Medycznej, GdaDsk
Oddział Chemioterapii, Olsztyn
Klinika Katedry Onkologii AM, Poznan
San Juan Medical Center, San Juan
Kiev Central Military Clinical Hospital, Kiev
Kiev Oncology Institute of Ukrainian Academy of Medical Science, Kiev
Addenbrookes Hospital, Cambridge
Royal Free Hospital, London
Hammersmith Hospital, London
Christie Hospital, Manchester
Lead Sponsor
Tularik
INDUSTRY